Upadacitinib (15 and 30 mg) was evaluated in adolescents with moderate to severe AD aged 12 to 17 years, with and without topical corticosteroids.
Joshua Fitch
Advertisement
Articles by Joshua Fitch
The ACIP was unanimous in its recommendation for routine use of nirsevimab-alip to prevent RSV LRTD in newborns and young infants during their first RSV season.
FDA approval of the monoclonal antibody against RSV follows the unanimous vote from the agency's Antimicrobial Drugs Advisory Committee.
Advertisement
Latest Updated Articles
FDA Approves Nirsevimab-alip Injection to Prevent RSV in Neonates, InfantsPublished: July 17th 2023 | Updated:
- Nirsevimab-alip Gets Unanimous ACIP Recommendation to Prevent RSV in Neonates, Infants
Published: August 3rd 2023 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive
2
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
3
Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...
4
Identifying and Managing Vascular Disease in Primary Care: A Q&A With Family Physician Kabiul Haque, MD
5
